AR061357A1 - COMBINATION PREPARATIONS INCLUDING BIFEPRUNOX AND L- DOPA - Google Patents

COMBINATION PREPARATIONS INCLUDING BIFEPRUNOX AND L- DOPA

Info

Publication number
AR061357A1
AR061357A1 ARP070102582A ARP070102582A AR061357A1 AR 061357 A1 AR061357 A1 AR 061357A1 AR P070102582 A ARP070102582 A AR P070102582A AR P070102582 A ARP070102582 A AR P070102582A AR 061357 A1 AR061357 A1 AR 061357A1
Authority
AR
Argentina
Prior art keywords
bifeprunox
dopa
preparations including
combination preparations
treatment
Prior art date
Application number
ARP070102582A
Other languages
Spanish (es)
Inventor
Martinus Th M Tulp
Andrew C Mccreary
Scharrenburg Gustaaf J M Van
Original Assignee
Solvay Pharm Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Solvay Pharm Bv filed Critical Solvay Pharm Bv
Publication of AR061357A1 publication Critical patent/AR061357A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente se refiere al uso de una preparacion combinada de bifeprunox o su N-oxido o sales farmacéuticamente aceptables de estos compuestos: y L-DOPA, para el uso simultáneo, separado o secuencial en el tratamiento de trastornos que requieren la recuperacion de la funcion dopaminérgica, en particular la enfermedad de Parkinson y el síndrome de las piernas inquietas. Composicion farmacéutica, método de tratamiento.This refers to the use of a combined preparation of bifeprunox or its N-oxide or pharmaceutically acceptable salts of these compounds: and L-DOPA, for simultaneous, separate or sequential use in the treatment of disorders that require recovery of function. dopaminergic, particularly Parkinson's disease and restless legs syndrome. Pharmaceutical composition, treatment method.

ARP070102582A 2006-06-16 2007-06-13 COMBINATION PREPARATIONS INCLUDING BIFEPRUNOX AND L- DOPA AR061357A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06115587 2006-06-16

Publications (1)

Publication Number Publication Date
AR061357A1 true AR061357A1 (en) 2008-08-20

Family

ID=37156018

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070102582A AR061357A1 (en) 2006-06-16 2007-06-13 COMBINATION PREPARATIONS INCLUDING BIFEPRUNOX AND L- DOPA

Country Status (7)

Country Link
CN (1) CN101478990A (en)
AR (1) AR061357A1 (en)
BR (1) BRPI0713691A2 (en)
MX (1) MX2008016226A (en)
SA (1) SA07280316B1 (en)
TW (1) TW200815031A (en)
UA (1) UA94465C2 (en)

Also Published As

Publication number Publication date
SA07280316B1 (en) 2010-10-19
BRPI0713691A2 (en) 2012-10-30
MX2008016226A (en) 2009-01-19
TW200815031A (en) 2008-04-01
CN101478990A (en) 2009-07-08
UA94465C2 (en) 2011-05-10

Similar Documents

Publication Publication Date Title
CL2007001918A1 (en) SUBSTITUTED HETEROARILY DERIVATIVE COMPOUNDS; METHOD FOR THE PREPARATION OF COMPOUNDS; PHARMACEUTICAL COMPOSITION; AND USE FOR THE TREATMENT OF PAIN, DEPRESSION, ALZHEIMER'S DISEASE AND HYPERTENSION BETWEEN OTHERS.
DOP2011000373A (en) DERIVATIVES OF 1H-IMIDAZO- [4,5-C] -QUINOLINONA
NI201000193A (en) ORAL FORMULATIONS OF CITIDINE ANALOGUES AND METHODS OF USE OF THE SAME.
CL2007003609A1 (en) COMPOUNDS DERIVED FROM REPLACED DIHYDROPIRIDINES; PREPARATION PROCESS; INTERMEDIARY COMPOUNDS; PHARMACEUTICAL COMPOSITION; PROCESS TO PRODUCE PHARMACEUTICAL COMPOSITION; AND USE IN THE TREATMENT OF A DISEASE IMPROVED WITH INHIBITION
CL2009000349A1 (en) Compounds derived from 4,5-dihydro-oxazol-2-ylamine; preparation procedure; pharmaceutical composition; and its use for the treatment of Alzheimer's disease.
PA8772101A1 (en) IMIDAZOL-TRIAZOLOPIRIMIDINAS REPLACED
BRPI0509655A (en) use of 9h-purine-2,6-diamine derivatives in the treatment of proliferative diseases and new 9h-purine-2,6-diamine derivatives
ECSP088974A (en) IMIDAZOL PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF DISEASES RELATED TO THE SYNTHEOSE QUINASA GLYCOGEN (GSK3)
AR056080A1 (en) 7- [2- [4- (6-FLUORO-3-METIL-1,2-BENCIOSOXAZOL-5-IL) -1-PIPERAZINIL] ETIL] -2- (1-PROPINYL) -7H-PIRAZOL- [4, 3-E] - [1,2,4] -TRIAZOL- [1,5-C] -PIRIMIDIN-5-AMINE
UY32691A (en) 1H-IMIDAZO- [4,5-C] -QUINOLINONA COMPOUNDS
BRPI0908124A2 (en) Compound, glucokinase activator, pharmaceutical composition, use of a pharmaceutically acceptable salt or compound thereof, and methods of activating glucokinase, and to treat and / or prevent a disease.
AR063538A1 (en) TREATMENT OF PARKINSON'S DISEASE
BRPI0814666A2 (en) pharmaceutical composition for oral administration, use of a formulation. process for preparing a solid dosage form, and, solid dosage form
AR070025A1 (en) USE OF DERIVATIVES OF 1-AMINO-ALQUILCICLOHEXANO FOR THE TREATMENT OF COCLEAR TINNITUS AND PHARMACEUTICAL COMPOSITION
CL2007002511A1 (en) COMPOSITES DERIVED FROM PIRROLO [2,3-F] ISOQUINOLINA, INHIBITORS OF KINASE-2; PREPARATION PROCESS; PHARMACEUTICAL COMPOSITION; PHARMACEUTICAL COMBINATION; AND USE FOR THE TREATMENT OF AN AUTOIMMUNE DISEASE.
BRPI0607413A2 (en) pharmaceutical composition comprising indolylmaleimide derivatives
CL2007002574A1 (en) ORAL PHARMACEUTICAL COMPOSITION INCLUDING LEVODOPA IN A UNIT DOSE OF AROUND 100 TO AROUND 500 MG AND AN ADEQUATE EXCIPIENT; AND ITS USE TO TREAT PARKINSON.
UY31839A (en) COMPOUNDS
EA200970022A1 (en) COMBINED PREPARATIONS CONTAINING BIFEPRUNOX AND L-DOSP
CL2007000789A1 (en) Malonamide derived compounds, gamma-secretase inhibitors; Preparation process; pharmaceutical composition; and its use in the treatment of Alzheimer's disease.
UY31903A (en) 7-SULFANILMETIL-, 7-SILFINILMETIL-Y7-SULFONILMETILINDOLES REPLACED AND THE USE OF THE SAME
UY30126A1 (en) A NEW PHARMACEUTICALLY ACCEPTABLE SALT OF 2-HIDROXI-3- (5- (MORFOLIN-4-ILMETIL) -PIRIDIN-2-L) 1H-INDOL-5-CARBONITRILE, PROCEDURES FOR THE PREPARATION, COMPOSITIONS CONTAINING IT AND APPLICATIONS
PE20030277A1 (en) PHARMACEUTICAL COMPOSITION INCLUDING 2- [5- (4-FLUOROPHENIL) -3-PYRIDYLMETHYLAMINOMETHYL] -CHROMANE AND L-DOPA
CL2008002465A1 (en) Topical anhydrous pharmaceutical composition, comprising niacin derivatives and an acceptable carrier, its application allows improved sexual well-being.
AR061357A1 (en) COMBINATION PREPARATIONS INCLUDING BIFEPRUNOX AND L- DOPA

Legal Events

Date Code Title Description
FA Abandonment or withdrawal